A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRATM) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer.
- Frentzas, Sophia (Primary Chief Investigator (PCI))
Project: Research